Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	2,963	3,118	2,488	2,730	3,106	2,886
Short-Term Investments	5,791	5,487	6,524	8,115	4,636	2,809
Cash & Short-Term Investments	8,754	8,605	9,013	10,845	7,742	5,695
Cash Growth	4.84%	-4.52%	-16.90%	40.07%	35.96%	58.76%
Accounts Receivable	5,731	5,741	6,212	5,667	5,329	6,037
Inventory	3,104	3,201	3,087	2,581	2,402	1,951
Other Current Assets	620.9	474.8	349.2	386.6	411.2	332.4
Total Current Assets	18,209	18,022	18,661	19,479	15,884	14,015
Net Property, Plant & Equipment	5,266	5,120	4,600	4,146	3,763	3,482
Other Intangible Assets	1,287	1,257	1,149	1,039	915.5	6.7
Long-Term Investments	9,786	10,261	8,900	5,397	6,592	6,838
Other Long-Term Assets	6,321	5,898	4,450	3,020	2,060	1,093
Total Assets	40,869	40,559	37,759	33,080	29,215	25,435
Accounts Payable	1,027	939	789.5	606.6	589.2	564
Accrued Expenses	2,724	2,876	2,527	2,358	2,074	2,207
Current Portion of Leases	720	-	-	-	-	719.7
Unearned Revenue	636.2	553	627.7	458.9	477.9	442
Total Current Liabilities	5,108	4,368	3,944	3,423	3,141	3,933
Long-Term Debt	1,986	1,986	1,984	1,983	1,981	1,980
Long-Term Leases	-	720	720	720	720	-
Other Long-Term Liabilities	2,351	2,228	1,757	980.8	707.8	753.5
Total Long-Term Liabilities	4,338	4,933	4,462	3,684	3,409	2,734
Total Liabilities	9,445	9,302	8,406	7,107	6,551	6,666
Common Stock	0.1	0.1	0.1	0.1	0.1	0.1
Treasury Stock	-19,414	-18,613	-15,167	-12,560	-10,353	-8,261
Additional Paid-in Capital	14,401	13,995	12,856	11,354	9,949	8,088
Accumulated Other Comprehensive Income	11.9	77.5	-7.9	-80.9	-238.8	-26.2
Retained Earnings	36,424	35,797	31,673	27,260	23,307	18,968
Shareholders' Equity	31,424	31,257	29,354	25,973	22,664	18,769
Total Liabilities & Equity	40,869	40,559	37,759	33,080	29,215	25,435
Total Debt	2,706	2,706	2,704	2,703	2,701	2,700
Net Cash (Debt)	6,048	5,899	6,308	8,142	5,041	2,995
Net Cash Growth	2.51%	-6.48%	-22.52%	61.52%	68.31%	236.03%
Net Cash Per Share	56.13	54.32	54.80	71.61	44.41	26.69
Book Value	31,424	31,257	29,354	25,973	22,664	18,769
Book Value Per Share	291.63	287.82	255.03	228.44	199.68	167.28
Tangible Book Value	30,137	30,000	28,205	24,935	21,749	18,762
Tangible Book Value Per Share	279.69	276.24	245.05	219.30	191.62	167.22

Updated Apr 29, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q